EA201001326A1 - STERILE OPHTHALMOLOGICAL COMPOSITIONS AND METHOD FOR THEIR PRODUCTION - Google Patents

STERILE OPHTHALMOLOGICAL COMPOSITIONS AND METHOD FOR THEIR PRODUCTION

Info

Publication number
EA201001326A1
EA201001326A1 EA201001326A EA201001326A EA201001326A1 EA 201001326 A1 EA201001326 A1 EA 201001326A1 EA 201001326 A EA201001326 A EA 201001326A EA 201001326 A EA201001326 A EA 201001326A EA 201001326 A1 EA201001326 A1 EA 201001326A1
Authority
EA
Eurasian Patent Office
Prior art keywords
production
ophthalmological compositions
sterile
sterile ophthalmological
compositions
Prior art date
Application number
EA201001326A
Other languages
Russian (ru)
Inventor
Ашок Васантрай Вайас
Равиндра Тукарам Джадхав
Субхаш Тримбак Фад
Original Assignee
Марвел Лайфсайнсез Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Марвел Лайфсайнсез Лтд. filed Critical Марвел Лайфсайнсез Лтд.
Publication of EA201001326A1 publication Critical patent/EA201001326A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Раскрыта офтальмологическая композиция, включающая 3-гидрокси-2,4,6-триметилпиридин, его фармацевтически приемлемые соли, сложные эфиры, производные и полиморфные модификации для лечения внутриглазного кровотечения и дегенерации желтого пятна.An ophthalmic composition is disclosed, including 3-hydroxy-2,4,6-trimethylpyridine, its pharmaceutically acceptable salts, esters, derivatives and polymorphic modifications for the treatment of intraocular bleeding and macular degeneration.

EA201001326A 2008-02-19 2009-02-19 STERILE OPHTHALMOLOGICAL COMPOSITIONS AND METHOD FOR THEIR PRODUCTION EA201001326A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN355MU2008 2008-02-19
PCT/IN2009/000113 WO2009116076A2 (en) 2008-02-19 2009-02-19 Sterile opthalmic preparations and a process for preparation thereof

Publications (1)

Publication Number Publication Date
EA201001326A1 true EA201001326A1 (en) 2011-04-29

Family

ID=41091336

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001326A EA201001326A1 (en) 2008-02-19 2009-02-19 STERILE OPHTHALMOLOGICAL COMPOSITIONS AND METHOD FOR THEIR PRODUCTION

Country Status (4)

Country Link
EP (1) EP2265252A2 (en)
CN (1) CN102006872A (en)
EA (1) EA201001326A1 (en)
WO (1) WO2009116076A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2252265A4 (en) * 2008-02-19 2011-04-20 Marvel Lifesciences Ltd Injectable preparations and a process of preparation thereof
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
CN102526282A (en) * 2012-03-11 2012-07-04 周洁 External-use health care product for lowering intraocular pressure of diabetes mellitus eye disease patient
EP3530262A1 (en) 2018-02-27 2019-08-28 The Procter & Gamble Company Personal care compositions and uses
CN109030474A (en) * 2018-06-13 2018-12-18 迦娜生物科技（武汉）有限公司 A kind of lipid free radical urine detection reagent and its application
EP3842041A4 (en) * 2018-08-17 2022-04-13 Nibec Co., Ltd. Composition for treating and preventing gingivoperiodontitis or peri-implantitis, and interdental brush coated with same
RU2703306C1 (en) * 2018-09-27 2019-10-16 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Method for increasing visual functions in endovitreal surgery of rhegmatogenous detachment of the retina

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2276138C2 (en) * 2004-05-12 2006-05-10 Марвел Лайф Сайнсез Лтд. Substance possessing antioxidant, geroprotecting and anti-ischemic activity and method for its preparing

Also Published As

Publication number Publication date
EP2265252A2 (en) 2010-12-29
CN102006872A (en) 2011-04-06
WO2009116076A2 (en) 2009-09-24
WO2009116076A3 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
EA201001326A1 (en) STERILE OPHTHALMOLOGICAL COMPOSITIONS AND METHOD FOR THEIR PRODUCTION
EP4365179A3 (en) Novel rapamycin derivatives
MY167602A (en) Amine derivatives compounds for treating ophthalmic diseases and disorders
EA201100654A1 (en) CONNECTIONS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS
EA200700109A1 (en) METHODS OF TREATMENT OF OPHTHALMOLOGICAL CONDITIONS (OPTIONS)
UY30058A1 (en) (INDAZOL-5-IL) -PIRACINAS AND (1,3-DIHIDRO-INDOL-2-ON) -PIRACINAS FOR THE TREATMENT OF DISEASES AND AFFECTIONS MEDIATED BY RHO KINASE
WO2009091374A3 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
MX2009000531A (en) Fused heterocyclic derivatives and methods of use.
MX2021010888A (en) Heteroaromatic and heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders.
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
EA201071413A1 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF INCREASE IN-PRESSURE AND GLAUCOMA
EA201001328A1 (en) ORAL DOSED COMPOSITIONS AND METHOD FOR THEIR PRODUCTION
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
EA201100462A1 (en) SERIOUS CONNECTIONS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS
RU2012107109A (en) BICYCLIC COMPOUND AND ITS APPLICATION FOR MEDICAL PURPOSES
EP3870170A4 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
WO2018209363A3 (en) Propionic acid derivatives and methods of use thereof
WO2011053768A3 (en) System and method for stabilizing corneal tissue after treatment
MX2014002107A (en) (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders.
AR062395A1 (en) USE OF DERIVATIVES OF 2.5-DIHYDROXIBENCEN FOR THE TREATMENT OF EYE DISEASES
NZ754944A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
EP4100406A4 (en) Compositions for treatment of ocular diseases
MX2012001529A (en) 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators.
NZ598490A (en) Treatment of macular degeneration
BR112012016128A8 (en) THERAPEUTIC AGENT (Y-39983) FOR CORNEAL ENDOTHELIAL DYSFUNCTION